Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 15Neoplasms, Hormone-Dependent 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Triple Negative Breast Neoplasms 1Recurrence 1Neoplasm Metastasis 1Hormone-receptor-positive Breast Cancer 1Breast Carcinoma In Situ 1Breast Cancer Patients in Premenopausal 1Breast Cancer Organoids 1

Interventions

Tamoxifen 21Radiotherapy 9Chemotherapy, Adjuvant 9Specimen Handling 8Early Intervention, Educational 8Anastrozole 7Neoadjuvant Therapy 6Methods 6Letrozole 6Psychiatric Rehabilitation 5Practice Guidelines as Topic 5Immunohistochemistry 5Counseling 5Biopsy 5Standard of Care 4Mastectomy, Segmental 4Mass Spectrometry 4Magnetic Resonance Spectroscopy 4Gene Expression Profiling 4Educational Status 4Behavior Therapy 4exemestane 3Radiation Dose Hypofractionation 3Radiation 3Brachytherapy 3Watchful Waiting 2Therapeutics 2Telemedicine 2Taxes 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Carcinoma In Situ × Toremifene × Breast × Clear all
NCT03238703 2018-12-27

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Fred Hutchinson Cancer Center

Phase 4 Withdrawn
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡